Standard BioTools (LAB) Set to Announce Earnings This Wednesday

Standard BioTools (NASDAQ:LAB) is scheduled to release its quarterly earnings report after the market closes on Wednesday, February 26. Analysts predict that the company will report a loss of ($0.03) per share along with revenue of approximately $43.03 million for the quarter. For those interested in participating in the earnings conference call, registration can be completed at the provided link.

Current Stock Performance

As of Wednesday, Standard BioTools' stock opened at $1.40. Over the past periods, the stock has shown a fifty-day moving average of $1.73 and a two-hundred-day moving average of $1.82. Currently, the stock has a 52-week low of $1.17 and a 52-week high of $3.04. The company's market capitalization stands at $521.16 million with a price-to-earnings ratio of -1.97 and a beta value of 1.57, indicating its volatility compared to the market.

Analyst Insights

In related news, TD Cowen recently adjusted their price target for Standard BioTools, lowering it from $2.75 to $2.50 while maintaining a "buy" rating in a research note dated October 31.

About Standard BioTools

Standard BioTools Inc, along with its subsidiaries, focuses on providing a wide range of instruments, consumables, reagents, and software services to researchers and clinical laboratories in various regions, including the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two key segments: Proteomics and Genomics, and offers advanced analytical systems such as the CyTOF XT System and Hyperion XTi imaging system for high-parameter single-cell analysis and spatial biology.

Standard, BioTools, Earnings